Natera, Inc. (NASDAQ:NTRA) Shares Bought by Capital Fund Management S.A.

Capital Fund Management S.A. lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 59.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 133,851 shares of the medical research company's stock after acquiring an additional 50,061 shares during the quarter. Capital Fund Management S.A. owned approximately 0.10% of Natera worth $21,189,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Blue Trust Inc. raised its stake in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc raised its stake in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after buying an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after acquiring an additional 261 shares during the last quarter. Principal Securities Inc. boosted its stake in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after buying an additional 332 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Remove Ads

Natera Stock Performance

NASDAQ:NTRA traded up $0.41 during trading hours on Monday, reaching $148.45. 887,252 shares of the company's stock were exchanged, compared to its average volume of 1,394,376. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $20.07 billion, a price-to-earnings ratio of -84.35 and a beta of 1.80. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00. The company has a 50-day moving average of $152.09 and a 200 day moving average of $152.40.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity at Natera

In related news, insider John Fesko sold 663 shares of the company's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the sale, the insider now owns 156,044 shares of the company's stock, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 78,553 shares of the firm's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. This represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 325,922 shares of company stock worth $51,603,664 over the last 90 days. Company insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NTRA. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. Piper Sandler boosted their price objective on Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. The Goldman Sachs Group lifted their price target on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Robert W. Baird lifted their target price on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Finally, Sanford C. Bernstein raised their price target on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $175.76.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.